|
1
|
Henderson SM, Bradley K, Day MJ, Tasker S,
Caney SM, Hotston Moore A and Gruffydd-Jones TJ: Investigation of
nasal disease in the cat-a retrospective study of 77 cases. J
Feline Med Surg. 6:245–257. 2004.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Mukaratirwa S, van der Linde-Sipman JS and
Gruys E: Feline nasal and paranasal sinus tumours:
Clinicopathological study, histomorphological description and
diagnostic immunohistochemistry of 123 cases. J Feline Med Surg.
3:235–245. 2001.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Couto CG: Chapter 80: Lymphoma in the cat
and dog. In: Nelson RW Couto CG (eds.). Small animal internal
medicine, 4th edition. St. Louis, Elsevier. pp1174–1186. 2009.
|
|
4
|
Haney SM, Beaver L, Turrel J, Clifford CA,
Klein MK, Crawford S, Poulson JM and Azuma C: Survival analysis of
97 cats with nasal lymphoma: A multi-institutional retrospective
study (1986-2006). J Vet Intern Med. 23:287–294. 2009.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Pinard CL, Mutsaers AJ, Mayer MN and Woods
JP: Retrospective study and review of ocular radiation side effects
following external-beam Cobalt-60 radiation therapy in 37 dogs and
12 cats. Can Vet J. 53:1301–1307. 2012.PubMed/NCBI
|
|
6
|
Knapp DW, Richardson RC, Bonney PL and
Hahn K: Cisplatin therapy in 41 dogs with malignant tumors. J Vet
Intern Med. 2:41–46. 1988.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Machado MC, da Costa-Neto JM, Portela RD,
D'Assis MJMH, Martins-Filho OA, Barrouin-Melo SM, Borges NF, Silva
FL and Estrela-Lima A: The effect of naltrexone as a carboplatin
chemotherapy-associated drug on the immune response, quality of
life and survival of dogs with mammary carcinoma. PLos One.
13(e0204830)2018.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Oun R, Moussa YE and Wheate NJ: The side
effects of platinum-based chemotherapy drugs: A review for
chemists. Dalton Trans. 47:6645–6653. 2018.PubMed/NCBI View Article : Google Scholar
|
|
9
|
O'Reilly S, Rowinsky E, Slichenmyer W,
Donehower RC, Forastiere A, Ettinger D, Chen TL, Sartorius S,
Bowling K, Smith J, et al: Phase I and pharmacologic studies of
topotecan in patients with impaired hepatic function. J Natl Cancer
Inst. 88:817–824. 1996.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Radzi R, Osaki T, Tsuka T, Imagawa T,
Minami S, Nakayama Y and Okamoto Y: Photodynamic hyperthermal
therapy with indocyanine green (ICG) induces apoptosis and cell
cycle arrest in B16F10 murine melanoma cells. J Vet Med Sci.
74:545–551. 2012.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Urbanska K, Romanowska-Dixon B, Matuszak
Z, Oszajca J, Nowak-Sliwinska P and Stochel G: Indocyanine green as
a prospective sensitizer for photodynamic therapy of melanomas.
Acta Biochim Pol. 49:387–391. 2002.PubMed/NCBI
|
|
12
|
Porcu EP, Salis A, Gavini E, Rassu G,
Maestri M and Giunchedi P: Indocyanine green delivery systems for
tumour detection and treatments. Biotechnol Adv. 34:768–789.
2016.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Suganami A, Toyota T, Okazaki S, Saito K,
Miyamoto K, Akutsu Y, Kawahira H, Aoki A, Muraki Y, Madono T, et
al: Preparation and characterization of phospholipid-conjugated
indocyanine green as a near-infrared probe. Bioorg Med Chem Lett.
22:7481–7485. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Xue X, Fang T, Yin L, Jiang J, He Y, Dai Y
and Wang D: Multistage delivery of CDs-DOX/ICG-loaded liposome for
highly penetration and effective chemo-photothermal combination
therapy. Drug Deliv. 25:1826–1839. 2018.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Fang J, Nakamura H and Maeda H: The EPR
effect: Unique features of tumor blood vessels for drug delivery,
factors involved, and limitations and augmentation of the effect.
Adv Drug Deliv Rev. 63:136–151. 2011.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Matsumura Y and Maeda H: A new concept for
macromolecular therapeutics in cancer chemotherapy: Mechanism of
tumoritropic accumulation of proteins and the antitumor agent
smancs. Cancer Res. 46:6387–6392. 1986.PubMed/NCBI
|
|
17
|
Toyota T, Fujito H, Suganami A, Ouchi T,
Ooishi A, Aoki A, Onoue K, Muraki Y, Madono T, Fujinami M, et al:
Near-infrared-fluorescence imaging of lymph nodes by using
liposomally formulated indocyanine green derivatives. Bioorg Med
Chem. 22:721–727. 2014.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Suganami A, Iwadate Y, Shibata S,
Yamashita M, Tanaka T, Shinozaki N, Aoki I, Saeki N, Shirasawa H,
Okamoto Y and Tamura Y: Liposomally formulated
phospholipid-conjugated indocyanine green for intra-operative brain
tumor detection and resection. Int J Pharm. 496:401–406.
2015.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Maruyama T, Akutsu Y, Suganami A, Tamura
Y, Fujito H, Ouchi T, Akanuma N, Isozaki Y, Takeshita N, Hoshino I,
et al: Treatment of near-infrared photodynamic therapy using a
liposomally formulated indocyanine green derivative for squamous
cell carcinoma. PLoS One. 10(e0122849)2015.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Shibata S, Shinozaki N, Suganami A,
Ikegami S, Kinoshita Y, Hasegawa R, Kentaro H, Okamoto Y, Aoki I,
Tamura Y and Iwadate Y: Photo-immune therapy with liposomally
formulated phospholipid-conjugated indocyanine green induces
specific antitumor responses with heat shock protein-70 expression
in a glioblastoma model. Oncotarget. 10:175–183. 2019.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ,
Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al:
Safety and activity of anti-PD-L1 antibody in patients with
advanced cancer. N Engl J Med. 366:2455–2465. 2012.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Gustafson DL and Page RL: Cancer
Chemotherapy. In: Withrow SJ Vail DM and Page RL (eds.). Small
animal clinical oncology, 5th edition. St. Louis, Elsevier.
pp157–179. 2012.
|
|
23
|
Kisseberth WC, Vail DM, Yaissle J, Jeglum
KA, Couto CG, Ward H, Khanna C and Obradovich JE: Phase I clinical
evaluation of carboplatin in tumor-bearing cats: A veterinary
cooperative oncology group study. J Vet Intern Med. 22:83–88.
2008.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Poirier VJ, Hershey AE, Burgess KE,
Phillips B, Turek MM, Forrest LJ, Beaver L and Vail DM: Efficacy
and toxicity of paclitaxel (Taxol) for the treatment of canine
malignant tumors. J Vet Intern Med. 18:219–222. 2004.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Zhang X, Liu Y, Kim YJ, Mac J, Zhuang R
and Wang P: Co-delivery of carboplatin and paclitaxel via
cross-linked multilamellar liposomes for ovarian cancer treatment.
RSC Adv. 7:19685–19693. 2017.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Harabuchi Y, Takahara M, Kishibe K, Nagato
T and Kumai T: Extranodal natural Killer/T-cell lymphoma, nasal
type: Basic science and clinical progress. Front Pediatr.
7(141)2019.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nagata K, Lamb M, Goldschmidt MH, Duda L
and Walton RM: The usefulness of immunohistochemistry to
differentiate between nasal carcinoma and lymphoma in cats: 140
Cases (1986-2000). Vet Comp Oncol. 12:52–57. 2014.PubMed/NCBI View Article : Google Scholar
|
